thc-20260527
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
_______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: May 27, 2026
(Date of earliest event reported)
_______________
TENET HEALTHCARE CORPORATION
(Exact name of registrant as specified in its charter)
Nevada | 1-7293 | 95-2557091 | ||||||||||||
| (State of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||||||||
_______________
14201 Dallas Parkway
Dallas, TX 75254
(Address of principal executive offices, including zip code)
(469) 893-2200
(Registrant’s telephone number, including area code)
_______________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common stock, $0.05 par value | THC | NYSE | ||||||||||||
| 6.875% Senior Notes due 2031 | THC31 | NYSE | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. | Submission of Matters to a Vote of Security Holders. | ||||
The 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Tenet Healthcare Corporation (the “Company”) was held on May 27, 2026. Below are the final voting results from the meeting.
1. The Company’s shareholders elected the following directors to serve on the Company’s Board of Directors, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected or qualified, whichever is later, or until the director’s earlier resignation or removal:
FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||||||||
Saumya Sutaria | 72,297,676 | 2,036,933 | 76,905 | 5,510,667 | ||||||||||||||||||||||
J. Robert Kerrey | 71,837,362 | 2,539,818 | 34,334 | 5,510,667 | ||||||||||||||||||||||
| Vineeta Agarwala | 73,763,259 | 621,321 | 26,934 | 5,510,667 | ||||||||||||||||||||||
James L. Bierman | 73,793,459 | 550,313 | 67,742 | 5,510,667 | ||||||||||||||||||||||
| Roy Blunt | 73,768,660 | 572,299 | 70,555 | 5,510,667 | ||||||||||||||||||||||
Richard W. Fisher | 73,759,704 | 583,669 | 68,141 | 5,510,667 | ||||||||||||||||||||||
Meghan M. FitzGerald | 73,162,461 | 1,222,005 | 27,048 | 5,510,667 | ||||||||||||||||||||||
Cecil D. Haney | 73,782,103 | 549,561 | 79,850 | 5,510,667 | ||||||||||||||||||||||
Christopher S. Lynch | 73,771,835 | 570,200 | 69,479 | 5,510,667 | ||||||||||||||||||||||
Richard J. Mark | 73,767,877 | 574,980 | 68,657 | 5,510,667 | ||||||||||||||||||||||
Tammy Romo | 73,149,469 | 1,233,024 | 29,021 | 5,510,667 | ||||||||||||||||||||||
Nadja Y. West | 73,659,093 | 710,537 | 41,884 | 5,510,667 | ||||||||||||||||||||||
2. The Company’s shareholders approved, on an advisory basis, the Company’s executive compensation:
FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||
| 62,554,346 | 11,817,273 | 39,895 | 5,510,667 | |||||||||||||||||
3. The Company’s shareholders approved the ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2026:
FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||
| 79,422,386 | 470,477 | 29,318 | — | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TENET HEALTHCARE CORPORATION | ||||||||
| Date: May 29, 2026 | By: | /s/ THOMAS ARNST | ||||||
| Name: Thomas Arnst | ||||||||
| Title: Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary | ||||||||